Home Research Research themes Emerging and re-emerging infections Protocols 2002012

2002012

A prospective, randomised, double blind, placebo-controlled,multi-centre trial to assess safety, efficacy, tolerability and immunogenicity of influenza virus vaccine, trivalent, types A & B, live cold-adapted, liquid formulation (CAIV-T), administered concomitantly with a combination live, attenuated, Mumps, Measles, and Rubella vaccine in healthy children aged 11-24 months.

Short Title CAIV-T P522
Protocol No 2002012
Status Completed
Keywords VACCINE, IMMUNOGENICITY, INFLUENZA, EFFICACY, NASAL SPRAY
Center Health Systems & Infectious Diseases
MDG(s) this protocol relates to
HPNSDP(s) this protocol relates to
PI Name Robert Fedric Breiman
Collaborating Institutes (169) Wyeth-Lederle Vaccines, USA
Funding
Summary
‹ Search All Protocols Here